Biological Innovation: Monoclonal antibodies, vaccines, cell therapies, gene therapies, peptide drugs, recombinant proteins, biosimilars, immunotherapies, CRISPR, gene editing, microbiome therapies, regenerative medicine, synthetic biology, exosome therapies, and innovative pharmaceuticals

Bio‑Intelligence: Diagnostic devices, therapeutic devices, monitoring equipment, IVDs, molecular diagnostics, pathology diagnostics, medical monitors, POCT, artificial intelligence and big data, digital health, wearable devices, AI‑powered biomedical imaging, telemedicine and remote patient monitoring, surgical robots, and home‑use medical devices

Bio‑Convergence: Analytical instruments, laboratory consumables, experimental equipment, reagents and supplies, biomaterials, industrial bioproducts, CROs, CMOs, CDMOs, testing services, consulting and training services, bioinformatics services, and measurement instruments

Bio‑Accelerators: Biopharmaceutical investment, venture capital, mergers and acquisitions, licensing and collaborations, initial public offerings and financing, government grants and subsidies, industry policies and regulations, market analysis and trends, technology transfer, incubators and accelerators, as well as corporate strategy and development